Pregabalin Capsule
Product Images NDC 82968-008

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82968-008). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fourrts (india) Laboratories Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Pregabalin 100mg 100s Carton)

Packaging label for Pregabalin Capsules 100 mg per capsule by Fourrts (India) Laboratories Private Limited. The package is for oral capsules with a count of 100 capsules, intended for in-institution use only. The label notes the product is made in India and includes storage instructions, manufacturer and distributor information, and a barcode.*

FDA Label Image

Image (Pregabalin 100mg 10s Blis)

Pregabalin Capsule 100 mg label showing multiple identical label stickers arranged in a grid. Each label displays the product name, strength, and dosage form, with distributor information for Fourrts LLC in Park Ridge, NJ. The label includes a barcode area, Rx Only designation, and lot/expiration date placeholders.*

FDA Label Image

Image (Pregabalin 100mg 90s Bot)

Label for Pregabalin Capsules 100 mg, an oral prescription drug by Fourrts (India) Laboratories Pvt. Ltd. The label includes dosage and storage instructions, quantity of 90 capsules, barcode, and manufacturing information indicating the product is made in India and distributed by Fourrts Pharmaceuticals USA LLC.*

FDA Label Image

Image (Pregabalin 150mg 100s Carton)

The packaging label for Pregabalin Capsules 150 mg per capsule by Fourrts Laboratories features a predominantly white background with blue highlights. The front and sides prominently display the product name, strength, and dosage form, with the statement 'For In-institution use only.' The package contains 100 capsules and includes storage instructions, manufacturer and distributor details, barcode, and regulatory information. The label indicates the product is made in India and includes an Rx only designation.*

FDA Label Image

Image (Pregabalin 150mg 10s Blis)

Label set for Pregabalin Capsule 150 mg in capsule form. Each label includes the name Pregabalin Capsule 150 mg, distributor Fourrts LLC located in Park Ridge, NJ 07656, a barcode section, the mark Rx Only, and a small CV logo on a white background with red borders separating each label.*

FDA Label Image

Image (Pregabalin 150mg 90s Bot)

Label for Pregabalin Capsules 150 mg by Fourrts (India) Laboratories Private Limited. The label includes dosage form (capsules), strength (150 mg), quantity (90 capsules), storage instructions, manufacturer and distributor information, an NDC number (82968-010-01), and a barcode. The label also notes it is Rx only and has an area reserved for lot and expiration overprinting.*

FDA Label Image

Image (Pregabalin 200mg 90s Bot)

Label for Pregabalin Capsules 200 mg by Fourrts (India) Laboratories Private Limited. The label indicates the medication is in capsule form, contains 200 mg pregabalin per capsule, and is available in a 90-capsule supply. It includes storage instructions, lot and expiration date areas, manufacturer and distributor information, and is marked Rx only.*

FDA Label Image

Image (Pregabalin 225mg 90s Bot)

Pregabalin Capsules 225 mg label from Fourrts Laboratories Pvt. Ltd. The label indicates a package containing 90 capsules, with storage instructions and dispensing guidance. It includes a barcode, lot, and expiration area, and mentions manufacturer details in India and distribution by Fourrts Pharmaceuticals USA LLC.*

FDA Label Image

Image Description (Pregabalin 25mg 90s Bot)

Label for Pregabalin Capsules 25 mg by Fourrts (India) Laboratories Private Limited. The label specifies 90 capsules per container, with storage instructions and a note to dispense the medication guide to each patient. It includes a barcode, lot and expiration printing areas, and distributor information for Fourrts Pharmaceuticals USA LLC in Park Ridge, NJ. The product is made in India and is prescription only.*

FDA Label Image

Image (Pregabalin 300mg 90s Bot)

Label for Pregabalin Capsules 300 mg oral capsules by Fourrts (India) Laboratories Pvt. Ltd. The label includes dosage instructions, storage conditions, lot and expiration date area for overprinting, barcode, manufacturer and distributor details, and prescription-only status. The package contains 90 capsules.*

FDA Label Image

Image (Pregabalin 50mg 100s Carton)

Packaging label for Pregabalin capsules, 50 mg per capsule, manufactured by Fourrts (India) Laboratories Private Limited. The label specifies 100 capsules per unit dose and indicates the product is for in-hospital use only. It includes storage instructions, manufacturing and distribution details, and a barcode.*

FDA Label Image

Image (Pregabalin 50mg 10s Blis)

Sheet of multiple labels for Pregabalin Capsule 50 mg by Fourrts (India) Laboratories Private Limited. Each label includes the drug name, strength, dosage form, distributor Fourrts LLC in Park Ridge, NJ, a barcode placeholder, and "Rx Only" marking. Labels are arranged in two columns and five rows with perforated lines for separation.*

FDA Label Image

Image (Pregabalin 50mg 90s Bot)

Label for Pregabalin Capsules 50 mg, oral dosage form, manufactured by Fourrts (India) Laboratories Pvt. Ltd. The label states the package contains 90 capsules. It includes directions for storage between 15°C to 30°C and advises dispensing in child-resistant containers. The label features the NDC number 82968-007-01, barcode, Rx only designation, and notes it is made in India and distributed by Fourrts Pharmaceuticals USA LLC.*

FDA Label Image

Image (Pregabalin 75mg 100s Carton)

PREGABALIN 75 mg capsules carton label from Fourrts (India) Laboratories Private Limited. The label shows storage instructions, dosage information, and a 100 capsules package size. The product is indicated as a human prescription drug for oral use, with the active ingredient strength clearly marked as 75 mg per capsule. The label includes manufacturer details, a barcode, and a warning that the product is for in-institution use only.*

FDA Label Image

Image (Pregabalin 75mg 10s Blis)

Labels for Pregabalin Capsule 75 mg showing the product name, dosage strength, and dosage form. The label indicates it is distributed by Fourrts LLC, Park Ridge, NJ 07656, and is marked Rx Only. Each label includes a barcode box and regulatory symbols.*

FDA Label Image

Image (Pregabalin 75mg 90s Bot)

Label for Pregabalin Capsules 75 mg by Fourrts (India) Laboratories Private Limited. The label includes dosage information, storage instructions, and states that the package contains 90 capsules. It indicates prescription-only status and provides manufacturer and distributor details, including Fourrts Pharmaceuticals USA LLC in New Jersey. A barcode and lot/expiration overprinting area are visible.*

FDA Label Image

Figure 6 (Pregabalin Bar 1)

A bar chart comparing responder rates (%) for different doses in two studies (E1 and E3). The x-axis shows placebo and various mg/day doses, while the y-axis represents responder rate percentages. The chart highlights statistically significant differences versus placebo with higher response rates at increasing doses.*

FDA Label Image

Figure 8 (Pregabalin Bar 2)

A bar chart showing responder rates (%) for three groups: Placebo (22.6%, n=93), 2.5 mg/kg/day (29.1%, n=103), and 10 mg/kg/day (40.6%, n=96). The vertical axis represents responder rate percentages, and the horizontal axis categorizes the treatment groups with sample sizes below each bar.*

FDA Label Image

Figure 1 (Pregabalin Fig 1)

A line graph depicting percent improvement in pain from baseline on the horizontal axis versus percent of patients improved on the vertical axis. The chart compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating differences in patient response rates across these treatments.*

FDA Label Image

Figure 12 (Pregabalin Fig 10)

A line graph comparing the percentage of subjects improved from baseline to week 16 BOCF, showing Pregabalin versus Placebo. The x-axis represents the percent improved, ranging from greater than 0 to 100, while the y-axis shows the percent of subjects improved, descending from 100 to 0. Two lines compare Pregabalin (solid) and Placebo (dashed) over the assessed improvement range.*

FDA Label Image

Figure 2 (Pregabalin Fig 2)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, showing higher patient improvement rates with Pregabalin across the pain improvement spectrum.*

FDA Label Image

Figure 3 (Pregabalin Fig 3)

A line graph showing the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. It compares Pregabalin 75 mg, 150 mg, and 300 mg taken two times a day against placebo, illustrating pain improvement levels among patients.*

FDA Label Image

Figure 4 (Pregabalin Fig 4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph displays higher improvement percentages for Pregabalin groups compared to placebo across various improvement levels.*

FDA Label Image

Figure 5 (Pregabalin Fig 5)

A line graph depicting the percent of patients improved over time measured as percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups, showing higher improvement percentages for the Pregabalin doses compared to placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig 6)

A line graph showing median percent reduction in seizures from baseline versus pregabalin dose (mg/day). Four studies (E1 BID, E2 TID, E3 BID, E3 TID) are plotted, each with distinct markers, indicating seizure reduction increases with higher doses up to 600 mg/day. Only statistically significant p-values are displayed on the chart.*

FDA Label Image

Figure 9 (Pregabalin Fig 7)

A line chart depicting several curves, likely representing data trends or comparisons over a range with a vertical axis from 0 to 100 and two vertical reference lines. The legend indicates four different line styles, suggesting multiple data series being compared.*

FDA Label Image

Figure 10 (Pregabalin Fig 8)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR (long-term response) over 180 days between Pregabalin and placebo groups. The vertical axis shows the estimated percentage from 0% to 100%, and the horizontal axis shows time in days from 0 to 180. The solid line represents Pregabalin, while the dashed line represents placebo, indicating higher estimated survival without LTR for Pregabalin over time.*

FDA Label Image

Figure 11 (Pregabalin Fig 9)

A line graph comparing the percent of subjects improved over time from baseline to week 12, measured by BOCF. The graph includes two lines representing Pregabalin and Placebo, with the Pregabalin line consistently showing higher percent improvements across the timeline up to 100 percent on the x-axis.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Formula depicting creatinine clearance (CLCr) calculation based on age, weight, serum creatinine, with an adjustment factor for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Structure)

Chemical structure of pregabalin, showing its molecular arrangement with an amino group, carboxylic acid group, and side chains consistent with the compound's known formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.